Providing Individuals &
Industry Personalized Care

A multi-therapeutic research center performing studies
in clinical medicine including Phases II through IV

Research for Answers to Better Health

Founded in 1999 for the Advancement of Medical Science

The founder and current medical director, Andrew W. Garner, MD, CPI has been doing clinical research since 1989. The research center was established for the advancement of medical science in the Adirondack area of Upstate New York. We are a multi-therapeutic research center performing studies in numerous areas of medicine including Phases II through IV.

Current
Studies

Gout

Diabetes Type 2

EDTA Chelation Therapy

TAU Brain Correlation Study

Please contact us by phone or email
if interested in our studies.

Dr. Garner is a Certified Physician Investigator through the Association of Clinical Research Professionals [ACRP]

Therapeutic areas include:

Depression

Osteoarthritis

COPD

Asthma

Anxiety

ASCVD

Infectious Disease

Hypertension

Metabolic Disease:
Diabetes Mellitus Type II

Alzheimers

Cognitive Impairment

Gout

Chronic Pain

Influenza Therapy

Post Herpetic Neuralgia

NADH Therapy

Hyperlipidemia

  • A multicenter, multinational, randomized, double-blind controlled clinical study of the efficacy and safety of oral telithromycin (800 mg) once a day for 5 days versus azithromycin (500 mg) once a day for day 1 then (250 mg) once a day for the remaining 4 days in the treatment of acute exacerbation of chronic bronchitis in adult outpatients with chronic obstructive pulmonary disease. Protocol HMR3647A/4014, Aventis Pharmaceuticals.
  • A 16-week, parallel-group, double-blind, randomized, placebo-controlled, multicenter, dose-ranging Phase II study to evaluate the efficacy, safety, and tolerability of multiple doses and multiple treatment regimens of GSK716155, with Byetta as an open-label active reference, in subjects with type 2 diabetes mellitus. Protocol GLP110125, GlaxoSmithKline.
  • A double-blind, randomized, placebo-controlled, 5-arm titration study to evaluate the efficacy and safety of TAK-491 when compared with valsartan and olmesartan in subjects with essential hypertension. Protocol 01-06-TL-491-019, Takeda Pharmaceuticals.
  • A randomized, double-blind, placebo-controlled, multiple-dose, phase II study to evaluate the efficacy and safety of 3 months of weekly injections of CJC-1134-PC in patients with type 2 diabetes mellitus on metformin monotherapy. Protocol DM200-101, ConjuChem Biotechnologies, Inc.
  • Gastrointestinal randomized event and safety open-label NSAID study [GI-REASONS]: A randomized, open-label, blinded-endpoint, parallel-group trial of GI safety of Celecoxib compared with non-selective nonsteroidal anti-inflammatory drugs [NSAIDS] in Osteoarthritis patients.
    Protocol A3191331/2950, Pfizer Pharmaceuticals.
  • A multicenter, randomized, open-label, parallel design trial to compare time to response in the symptoms of anxiety to concomitant treatment with Niravam and an SSRI or SNRI to treatment with an SSRI or SNRI alone in subjects with Generalized Anxiety Disorder or Panic Disorder.
    Protocol SP851. Schwarz Pharma.
  • An Open-Label, Multicenter Non-Comparative Study of Oral Gatifloxacin in the Treatment of Community-Acquired Respiratory Tract Infections (Acute Bacterial Exacerbation of Chronic Bronchitis, Acute Uncomplicated Maxillary Sinusitis, and Pneumonia).Protocol AI420-088. Bristol-Myers Squibb.       
  • A phase III, multicenter, randomized multiple-dose study: Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril [OCTAVE].  Protocol CV137-120.  Bristol-Myers Squibb.        
  • Randomized, open label, multicenter trial of the safety and effectiveness of Oral Telithromycin (Ketek) and Amoxicillin/Clavulanic Acid (Augmentin) in outpatients with respiratory infections in usual care settings. Protocol HMR3674A/3014. Aventis Pharmaceuticals.    
  • A Phase 3b, Double-Blind, Randomized, 12-week Efficacy and Safety  Study of the Compound TAK-491 plus Chlorothalidone Fixed-Dose Combination vs  Olmesartan Hydrochlorothaizide in Subjects with Moderate to Severe Essential Hypertension  Protocol number TAK-491CLD-303 Takeda Pharmaceuticals.
  • A Phase IIIb randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 micrograms Tiotropium inhaliation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18 micrograms delivered by the HandiHaler.  Protocol number 205.452  Boehringer-Ingelheim.
  • A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities. Protocol number TMX-67_301. Takeda Pharmaceuticals.
  • A Multi-center, Primary Care-Based, Open–Label, Study to Assess the Success of Converting Opioid Experienced patients, with Chronic, Moderate to Severe Pain, to EMBEDA™ Using a Standardized Conversion Guide, and to  Identify Behaviors Related to Prescription Opioid Abuse, Misuse and Diversion. Protocol ALO-01-10-4003.  King Pharmaceuticals.
  • A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of BI 10773 25 mg/linagliption 5mg and BI10772 10mg/linagliptin 5 mg Fixed Dose Combination tablets compared with the individual components (BI 10773 35 mg, BI 10773 10 mg, and linagliptin 5 mg) for 52 weeks in treatment naїve and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control. Protocol 1275.1  Boehringer-Ingelheim Pharmaceuticals
  • A 52-week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Roflumilast 500 ug on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS). Protocol ROF-MD-07  Forest Research Institute
  • A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential Hypertension. Protocol NAC-MD-01  Forest Research Institute
  • Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients with Type 2 Diabetes Mellitus.  Protocol AT851-U-12-002 Akros Pharma Inc.
  • A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety or Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol. Protocol RDEA594-301 Ardea Biosciences Inc.
  • A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension.  Protocol TMX-67_206 Takeda Global Research & Development Center, Inc.
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment with Ertugliflozin (MK-8835/F04971729) in Subjects with Type 2 Diabetes Mellitus and Established Vascular Disease.  Protocol MK-8835-004/B12521021 Pfizer and Merck & Co.
  • A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in patients with Type 2 Diabetes.  D513BC00001 Astra Zeneca
  • A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naive patients with uncontrolled type 2 diabetes mellitus.  Protocol LPS14347 Sanofi
  • A randomized, double blind controlled factorial clinical trial of edetate disodium-based Chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction.  Protocol 3UG3AT009149-01S1  The National Center of Complementary and Integrative Health
  • A Clinico-Pathological Study of the Corresponsence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology. 18F-AV-1451-A16 AVID Radiopharmaceuticals

Our Team

Medical Director

Andrew W. Garner, MD, CPI
agarner@adirondackmedicalresearch.com

Study Coordinator

Dawn Kalbfliesh, AAS
dkalb@adirondackmedicalresearch.com

Recruitment Director

Angela Annese, MA
aannese@adirondackmedicalresearch.com

Contracts Manager

John P. Neal
jneal@adirondackmedicalresearch.com

Administrator

Cindy Affinito
caffinito@adirondackmedicalresearch.com

Study Coordinator

April Andersen, LPN
aandersen@adirondackmedicalresearch.com

Business Manager

Stephen Olson, MBA, MAFM
solson@adirondackmedicalresearch.com

Study Coordinator

Darcy Black, RN
dblack@adirondackmedicalresearch.com

Study Coordinator

Lynelle Hauser, RN
lhauser@adirondackmedicalresearch.com

Contact Us

  • 8 Harrison Avenue Glens Falls, NY 12801
  • (518) 798-9401
  • (518) 615-0111
160D5327-0B46-450D-AFDE-7FB9370C4AB6